
ENHERTU® approved in the U.S. as first tumor agnostic HER2 directed therapy for previously treated patients with metastatic HER2 positive solid tumors
Daiichi Sankyo and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no satisfactory…